
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: June 12, 2025

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

**2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

On June 12, 2025, Legend Biotech Corporation (the “Company”) held its 2025 Annual General Meeting of Shareholders. The voting results are attached hereto as Exhibit 99.1.

This report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257625, 333-272222 and 333-278050) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

EXHIBIT INDEX

Exhibit Title

[99.1](#) [Voting Results of Annual General Meeting](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

Date: June 12, 2025

By: /s/ Ying Huang

Name: Ying Huang, Ph.D.

Title: Chief Executive Officer

Voting Results of 2025 Annual General Meeting

At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on June 12, 2025 (the "AGM"), the Company's shareholders:

- received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2024;
- ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending December 31, 2025;
- re-elected each of Dr. Patrick Casey, Mr. Yau Wai Man Philip and Dr. Fangliang Zhang to serve as a Class II director for a three-year term; and
- authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

A total of approximately 341,943,628 ordinary shares, including those underlying ADSs, representing approximately 92.8% of the ordinary shares issued and outstanding as of May 7, 2025, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:

Resolutions	For		Against		Abstain	
	Votes	%	Votes	%	Votes	%
Reception of Audited Financial Statements	341,805,292	92.737%	6,184	0.002%	132,152	0.036%
Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2025	341,855,596	92.750%	7,490	0.002%	80,542	0.022%
Election of Directors						
Dr. Patrick Casey (Class II)	336,842,366	91.390%	4,990,816	1.354%	110,446	0.030%
Mr. Yau Wai Man Philip (Class II)	318,544,258	86.425%	23,313,264	6.325%	86,106	0.023%
Dr. Fangliang Zhang (Class II)	327,927,312	88.971%	13,929,848	3.779%	86,468	0.023%
Authorization of Directors and Officers	341,728,190	92.716%	126,066	0.034%	89,372	0.024%